US 11,753,474 B2
Anti-Dectin-2 antibodies
Shelley Erin Ackerman, Redwood City, CA (US); David Dornan, Redwood City, CA (US); Karla A. Henning, Redwood City, CA (US); and Justin A. Kenkel, Redwood City, CA (US)
Assigned to Bolt Biotherapeutics, Inc., Redwood City, CA (US)
Filed by Bolt Biotherapeutics, Inc., Redwood City, CA (US)
Filed on Feb. 3, 2022, as Appl. No. 17/592,323.
Application 17/592,323 is a continuation of application No. PCT/US2021/030466, filed on May 3, 2021.
Claims priority of provisional application 63/018,952, filed on May 1, 2020.
Prior Publication US 2022/0153849 A1, May 19, 2022
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2851 (2013.01) [C07K 2317/565 (2013.01)] 131 Claims
 
1. A Dectin-2 binding agent comprising an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide, wherein, according to Kabat numbering:
the immunoglobulin heavy chain variable region polypeptide comprises a complementarity determining region 1 (HCDR1) comprising SEQ ID NO: 18, a complementarity determining region 2 (HCDR2) comprising SEQ ID NO: 49, and a complementarity determining region 3 (HCDR3) comprising SEQ ID NO: 83, and
the immunoglobulin light chain variable region polypeptide comprises a complementarity determining region 1 (LCDR1) comprising SEQ ID NO: 117, a complementarity determining region 2 (LCDR2) SEQ ID NO: 138, and a complementarity determining region 3 (LCDR3) comprising SEQ ID NO: 150.